23andme's prospects for survival dim

Genetic surveillance company 23andMe, once a $6bn prospect, is now a penny stock on the verge of doom. So 'what happens to all its DNA data?' asks NPR.

As 23andMe struggles for survival, customers like Wiles have one pressing question: What is the company's plan for all the data it has collected since it was founded in 2006?

— Read the rest
The post 23andme's prospects for survival dim appeared first on Boing Boing.